JP2009541319A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541319A5
JP2009541319A5 JP2009516542A JP2009516542A JP2009541319A5 JP 2009541319 A5 JP2009541319 A5 JP 2009541319A5 JP 2009516542 A JP2009516542 A JP 2009516542A JP 2009516542 A JP2009516542 A JP 2009516542A JP 2009541319 A5 JP2009541319 A5 JP 2009541319A5
Authority
JP
Japan
Prior art keywords
composition
biological substance
agent
biological
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009516542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541319A (ja
JP5319523B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/014274 external-priority patent/WO2007149433A2/en
Publication of JP2009541319A publication Critical patent/JP2009541319A/ja
Publication of JP2009541319A5 publication Critical patent/JP2009541319A5/ja
Application granted granted Critical
Publication of JP5319523B2 publication Critical patent/JP5319523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009516542A 2006-06-19 2007-06-19 リポソマーゼによる治療物質の腫瘍特異的送達 Active JP5319523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81454606P 2006-06-19 2006-06-19
US60/814,546 2006-06-19
PCT/US2007/014274 WO2007149433A2 (en) 2006-06-19 2007-06-19 Tumor-specific delivery of therapeutic agents via liposomase

Publications (3)

Publication Number Publication Date
JP2009541319A JP2009541319A (ja) 2009-11-26
JP2009541319A5 true JP2009541319A5 (https=) 2010-08-05
JP5319523B2 JP5319523B2 (ja) 2013-10-16

Family

ID=38834068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516542A Active JP5319523B2 (ja) 2006-06-19 2007-06-19 リポソマーゼによる治療物質の腫瘍特異的送達

Country Status (5)

Country Link
US (4) US8444963B2 (https=)
JP (1) JP5319523B2 (https=)
KR (1) KR101376634B1 (https=)
CN (1) CN101489593B (https=)
WO (1) WO2007149433A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210589B1 (en) * 2009-01-22 2015-05-06 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
US20130323167A1 (en) * 2010-10-21 2013-12-05 The Johns Hopkins University Detecting and treating solid tumors through selective disruption of tumor vasculature
KR20150037953A (ko) 2012-07-13 2015-04-08 각코호진 데이쿄 헤이세이 다이가쿠 항종양제, 종양 검출용 마커 및 경구 백신제
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
JP6495466B2 (ja) * 2015-10-07 2019-04-03 塩水港精糖株式会社 タキサン化合物を内包するリポソーム
EP4077359B1 (en) 2019-12-18 2026-03-18 LivingMed Biotech S.R.L. Genetically modified clostridium strains and uses thereof
US20250228902A1 (en) * 2022-03-23 2025-07-17 Riken Combination drug for treating malignant tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
JP2005298486A (ja) * 2004-03-15 2005-10-27 Nipro Corp リポソームを含む癌治療用医薬組成物
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Similar Documents

Publication Publication Date Title
JP2009541319A5 (https=)
Liang et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
Pastorino et al. Targeting liposomal chemotherapy via both tumor cell–specific and tumor vasculature–specific ligands potentiates therapeutic efficacy
Pujada et al. Matrix metalloproteinase MMP9 maintains epithelial barrier function and preserves mucosal lining in colitis associated cancer
Makky et al. Biomimetic liposomes and planar supported bilayers for the assessment of glycodendrimeric porphyrins interaction with an immobilized lectin
KR100386492B1 (ko) 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물
JP2019526578A (ja) キャリアー−ｐｄ−ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
JP7529754B2 (ja) がんを処置するための方法および組成物
JP2006513992A5 (https=)
CA3088122A1 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
KR101376634B1 (ko) 리포좀아제에 의한 치료제의 종양­특이적 전달
US20210162030A1 (en) Compositions and methods for treatment of cancer with lekti
KR20190013929A (ko) 약물-전달 나노입자 및 약물 내성암에 대한 치료
Alam et al. Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate)
CN113144172B (zh) 一种含有万古霉素、ir780与携氧全氟己烷的脂质体的制备方法
Stinchcombe et al. Current approaches to advanced-stage non–small-cell lung cancer: first-line therapy in patients with a good functional status
JP2026001029A (ja) がん治療のための化学療法剤とα－ラクトアルブミン－オレイン酸複合体の組合せ
Barzelighi et al. Investigating the effect of rAzurin loaded mesoporous silica nanoparticles enwrapped with chitosan-folic acid on breast tumor regression in BALB/C mice
Muñoz Madero et al. Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy
WO2005061531A1 (en) A superantigen fusion protein used for antitumor therapy and the preparation thereof
Mross et al. DNA-intercalators—the anthracyclines
Leighl et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
Cao et al. Neutrophil-hijacking vesicles suppress NET-mediated metastasis via targeted siRNA delivery after radiotherapy
CN118217416A (zh) 一种用于肿瘤治疗的载有凝血酶的四面体结构dna
Cortes-Funes et al. 5017 Multinational study (n= 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391